Table 3.
Medication | Dose/ Formulation |
Regimen | Mechanisms | Side Effects | References | ||
---|---|---|---|---|---|---|---|
TOPICAL | Antifungals | Ketoconazole | 2% Shampoo, cream, gel or foam | Scalp or skin: Twice/week × 4 weeks, then once/week for maintenance. | Inhibition of fungal cell wall synthesis. | ICD† in <1% of patients. Itching, burning sensation and dryness in 3% of patients. | [2,8,26,97–101] |
Bifonazole | 1% shampoo, cream or ointment | Scalp: every other day or once daily. Skin: once daily. |
ICD in 10% of patients. | [8,26,99,102] | |||
Miconazole | Cream | Skin: 1–2 times daily. | ICD, itching, burning sensation. | [47,97,103] | |||
Ciclopirox Olamine | 1.5% shampoo, cream, gel or lotion | Scalp: 2–3 times/week × 4 weeks, then once/week for maintenance. Skin: twice daily. |
Inhibition of metal-dependent enzymes. | ICD in <1% of patients. Itching, burning sensation in 2% of patients. | [8,47,97,99,104,105] | ||
Selenium sulfide | 2.5% shampoo | Scalp: Twice/week × 2 weeks, then once/week × 2 weeks. Repeat after 4–6 weeks. | Cytostatic and keratolytic. | ICD in ~3% of patients. Orange-brown scalp discoloration. | [8,97,106,107] | ||
Zinc Pyrithione | 1% shampoo | Scalp: 2–3 times/week. | Increased cellular copper interferes with iron-sulfur proteins. | ICD in ~3% of patients. | [8,97,99,101,108,109] | ||
Cortico-steroids | Hydrocortisone | 1% cream | Skin: 1–2 times daily. | Anti-inflammatory, anti-irritant. | Risk of skin atrophy, telangiectasias, folliculitis, hypertrichosis, and hypopigmentation with prolonged use. | [8,9,97,99,103,108] | |
Betamethasone dipropionate | 0.05% lotion | Scalp and skin: 1–2 times daily. | [8,47,110] | ||||
Desonide | 0.05% lotion, gel | Scalp and skin: 2 times daily. | [8,111–113] | ||||
Fluocinolone | 0.01% shampoo, lotion or cream | Scalp or skin: Once or twice daily. | [7,114] | ||||
Immuno-modulators | Pimecrolimus | 1% cream | Skin: 1–2 times daily. | Inhibition of cytokine production by T-lymphocyte. | Risk of skin malignancy and lymphoma with prolonged use. | [47,98,115–118] | |
Tacrolimus | 0.1% ointment | Skin: 1–2 times daily × 4 weeks, then twice/week for maintenance. | [26,97,109,118–120] | ||||
Miscellaneous | Coal tar | 4% shampoo | Scalp: 1–2 times/week. | Antifungal, anti-inflammatory, keratolytic, reduces sebum production. | Local folliculitis, ICD on fingers, psoriasis aggravation, skin atrophy, telangiectasias, hyper-pigmentation. Risk of squamous cell carcinoma with prolonged use. | [4,8,47,117,121] | |
Lithium gluconate/succinate | 8% ointment or gel | Skin: twice daily × 8 weeks. | Anti-inflammatory via increased IL-10 and decreased TLR2 and TLR4 in keratinocytes. | ICD in <10% of patients. | [8,122–124] | ||
Metronidazole | 0.75% gel | Skin: twice daily × 4 weeks. | Anti-inflammatory via inhibition of free radical species. | Rare contact sensitization with prolonged use. | [5,47,125,126] | ||
Phototherapy | UVB: Cumulative dose of 9.8 J/cm2 | Three time/week × 8 weeks or until clearing. | Immuno-modulation and inhibition of cell proliferation. | Burning, itching sensation during/after therapy. Risk of genital tumor with prolonged use. | [26,127–129] | ||
SYSTEMIC | Itraconazole | Oral: 200 mg | Once daily × 7 days, then once daily × 2 days/month for maintenance. | Inhibition of fungal cell wall synthesis. Anti-inflammatory via inhibition of 5-lipoxygenase metabolites. | Rare liver toxicity. | [97,130,131] | |
Terbinafine | Oral: 250 mg | Once daily × 4–6 weeks or 12 days monthly × 3 months. | Inhibition of cell membrane and cell wall synthesis. | Rare tachycardia and insomnia. | [132–134] |
Note: Shampoos, foams and lotions are better suited for treating seborrheic dermatitis and dandruff on the scalp; gels, creams and ointments are used to treat seborrheic dermatitis on body locations other than the scalp.
ICD: Irritant Contact Dermatitis.